Fosun Pharma
No. 2 East Fuxing Road
Shanghai
200010
China
Tel: 86-21-6332-5858
Fax: 86-21-6332-5028
Website: http://www.fosun.com/
About Fosun Pharma
113 articles about Fosun Pharma
-
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
12/14/2023
The Japan-based Global Health Innovative Technology Fund announced that it will invest approximately US$3.3 million in a global multicenter Phase III clinical trial project led by Fosun Pharma for a triple artemisinin combination drug against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.
-
Fosun Pharma USA and Treehill Partners launch joint efforts for capital investments in biopharma space
11/20/2023
Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical stage assets, further solidifying the relationship between the two companies.
-
Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure
8/30/2023
Shanghai Fosun Pharmaceutical Co., Ltd.* announced its 2023 Interim Results for the first half of 2023.
-
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
8/8/2023
Palatin Technologies, Inc. today announced that Fosun Pharma, the licensee of Vyleesi in China, reported its first sale in the Hainan Province of China.
-
Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa
6/6/2023
To support stronger healthcare delivery and outcomes in West Africa, Shanghai Fosun Pharmaceutical Co., Ltd. announced a deepening partnership with IFC to help the company build a pharmaceutical production facility and distribution hub in Côte d'Ivoire.
-
Fosun Pharma Participates in 2023 BIO International Convention to Demonstrate its Global Innovation Capabilities
6/6/2023
From June 5th to 8th (Pacific Standard Time), the 2023 BIO International Convention ("BIO 2023") will be held in Boston, Massachusetts , USA.
-
Fosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements
5/10/2023
From May 10 to 12, 2023, the 3rd BEYOND International Technology Innovation Expo — also known as BEYOND Expo 2023 is being held at the Venetian Macau Convention and Exhibition Center.
-
Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative
4/26/2023
On April 25, 2023, World Health Organization gave as the theme for World Malaria Day 2023 Time to deliver zero malaria: invest, innovate, implement.
-
Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement
3/28/2023
Shanghai Fosun Pharmaceutical Co., Ltd.*, a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced its 2022 annual results.
-
Syneos Health Announces Partnership with Fosun Pharma USA to Launch SerplulimabRelationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial Solutions
1/11/2023
Syneos Health today announced a strategic partnership with Fosun Pharma USA Inc.
-
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US
1/7/2023
Fosun Pharma has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody serplulimab in the United States.
-
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China
12/22/2022
BioNTech SE and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that the companies provided approximately 11,500 doses of mRNA-based COVID-19 vaccines which arrived on the Chinese Mainland on December 21, 2022.
-
Fosun Pharma's MSCI ESG Rating Upgraded to A
10/14/2022
The world's leading index company Morgan Stanley Capital International recently announced its latest annual Environmental, Social and Governance rating results.
-
Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively
3/22/2022
March 22, 2022, Shanghai Fosun Pharmaceutical Co., Ltd., a global innovation-driven pharmaceutical and healthcare industry group in China, announced its annual results for the year of 2021, together with its 2021 Corporate Social Responsibility report.
-
Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.
-
Fosun Pharma Announces 2021 Interim Results
8/24/2021
Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its interim results for the first half of 2021 ("the Reporting Period").
-
Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receipt of $15 Million Upfront Payment
9/29/2020
Polyphor AG announced the closing of the previously announced exclusive licensing agreement with Fosun Pharma for balixafortide in China.
-
Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012
9/17/2020
Raziel Therapeutics, a Pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market announces licensing of its disruptive technology, RZL-012, to Fosun Pharma for milestone
-
Fosun Pharma Announces 2020 Interim Results
8/26/2020
The Net Profit Attributable to Shareholders Increased 13.1% as Compared to the Same Period in 2019 with Innovation Transformation and Integrated Operation Actively Promoted [26-August-2020] SHANGHAI , Aug. 26, 2020 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK) , a leading healthcare group in Chin
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.